<p>馬薩諸塞州劍橋，2025 年 12 月 10 日（環球新聞通訊社）—— Fulcrum Therapeutics, Inc. <strong>®</strong>（“Fulcrum”）（納斯達克：FULC）是一家臨牀階段的生物製藥公司，專注於開發小分子藥物以改善基因定義的罕見疾病患者的生活，今天宣佈其之前宣佈的公開承銷發行的定價，發行 11,851,853 股普通股，公開發行價格為每股 13.50 美元，並且為了某些投資者提供預先融資的認股權證，以購買最多 1,111,193 股普通股，公開發行價格為每個預先融資認股權證 13.499 美元，這代表每股普通股的公開發行價格減去每個預先融資認股權證的 0.001 美元行使價格。Fulcrum 預計此次發行的總收入在扣除承銷折扣和佣金及其他發行費用之前，將達到 1.75 億美元。此外，Fulcrum 已授予承銷商一個 30 天的選擇權，以相同條款和條件購買最多 1,944,456 股普通股。所有發行的證券均由 Fulcrum 出售。</p>
<p>Fulcrum 目前打算將公開發行中證券銷售的淨收益主要用於一般企業用途，這可能包括營運資金和資本支出、研究與開發費用，包括資助臨牀試驗、監管提交、商業化、發現及額外的臨牀前研究與開發其他產品候選者和平台增強、一般和行政費用，以及潛在的收購或投資於補充其業務的公司、技術、產品或資產。</p>
<p>摩根大通、Leerink Partners 和 Cantor 擔任此次發行的賬簿管理經理。Oppenheimer &amp; Co.和 Truist Securities 也擔任此次發行的賬簿管理經理。此次發行需滿足慣例的成交條件，預計將於 2025 年 12 月 11 日左右完成。</p>
<p>這些證券是由 Fulcrum 根據之前於 2024 年 2 月 27 日向美國證券交易委員會（“SEC”）提交併於 2024 年 4 月 25 日獲得 SEC 批准的有效貨架註冊聲明進行發行的。此次發行僅通過書面招股説明書和招股説明書補充進行，這些文件構成註冊聲明的一部分。與此次發行相關的初步招股説明書補充及相關招股説明書已於 2025 年 12 月 8 日向 SEC 提交，並可在 SEC 的網站 www.sec.gov 上獲取，最終的招股説明書補充及相關招股説明書將與最終條款一起提交給 SEC。</p>
<p>當可用時，關於此次發行的最終招股説明書補充及相關招股説明書的副本可從摩根大通證券有限責任公司獲取，地址為：Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，NY 11717，或通過電子郵件發送至 prospectus-eq_fi@jpmorgan.com 和 postsalemanualrequests@broadridge.com；Leerink Partners LLC，注意：承銷部門，53 State Street，40th Floor，Boston，MA 02109，電話（800）808-7525，分機 6105，或通過電子郵件發送至 syndicate@leerink.com；Cantor Fitzgerald &amp; Co.，郵寄地址：注意：資本市場，110 East 59th Street，New York 10022，或通過電子郵件發送至 prospectus@cantor.com；Oppenheimer &amp; Co. Inc.，注意：承銷招股説明書部門，85 Broad Street，26th Floor，New York，NY 10004，或電話（212）667-8055，或通過電子郵件發送至 EquityProspectus@opco.com；或 Truist Securities, Inc.，注意：股本資本市場，740 Battery Ave SE，亞特蘭大，喬治亞州 30339，電話（800）685-4786 或通過電子郵件發送至 truistsecurities.prospectus@truist.com。</p>
<p>本新聞稿不構成出售這些證券的要約或購買這些證券的要約邀請，也不應在任何州或司法管轄區內進行這些證券的銷售，若在任何此類州或司法管轄區內的證券法下未進行註冊或資格審查，則該等要約、邀請或銷售將是非法的。</p>
<p><strong>關於 Fulcrum Therapeutics</strong></p>
<p>Fulcrum Therapeutics 是一家臨牀階段的生物製藥公司，專注於開發小分子藥物，以改善在高未滿足醫療需求領域中基因定義的罕見疾病患者的生活。Fulcrum 的主要臨牀項目是 pociredir，這是一種旨在增加胎兒血紅蛋白表達以治療鐮狀細胞病的小分子。Fulcrum 利用專有技術識別可以調節基因表達以治療基因誤表達已知根本原因的藥物靶點。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含 1995 年《私人證券訴訟改革法案》所定義的 “前瞻性聲明”，包括但不限於關於公開發行的完成及其收益使用的聲明。所有這些前瞻性聲明均基於管理層對未來事件的當前預期，並受到多種風險和不確定性的影響，這些風險和不確定性可能導致實際結果與這些前瞻性聲明中所列或暗示的結果存在重大和不利的差異。這些風險和不確定性與 Fulcrum 的股價波動、市場條件變化以及與公開發行相關的慣常成交條件的滿足有關，以及在上述招股説明書補充文件和註冊聲明的 “風險因素” 部分中討論的其他因素，以及 Fulcrum 最近提交的 10-Q 表格季度報告中詳細列出的其他風險。不能保證 Fulcrum 能夠按照預期條款完成公開發行。本新聞稿中的所有信息均截至發佈之日，Fulcrum 不承擔更新該信息的義務，即使後續事件導致其觀點發生變化，除非法律要求。</p>
<p><strong>聯繫方式：</strong></p>
<p>Kevin Gardner</p>
<p>LifeSci Advisors, LLC</p>
<p>kgardner@lifesciadvisors.com</p>
<p>617-283-2856</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01EQXhOU00zTXpFMU5UTTVJekl4T0RNMU5EST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01EQXhOU00zTXpFMU5UTTVJekl4T0RNMU5EST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Mzc4ZGRiYTEtNWUzMS00MTFjLThjOTgtNDRiYzZmNzlkY2MxLTExOTUxMDAtMjAyNS0xMi0xMC1lbg==/tiny/Fulcrum-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Mzc4ZGRiYTEtNWUzMS00MTFjLThjOTgtNDRiYzZmNzlkY2MxLTExOTUxMDAtMjAyNS0xMi0xMC1lbg==/tiny/Fulcrum-Therapeutics-Inc-.png"/></p>

FULC

<p>Fulcrum Therapeutics 宣佈其 1.75 億美元的普通股和預先融資認股權證的公開發行定價。此次發行包括 11,851,853 股，價格為每股 13.50 美元，以及 1,111,193 股的預先融資認股權證，價格為每股 13.499 美元。所得款項將用於公司用途，包括研發和潛在收購。此次發行由摩根大通、Leerink Partners 等管理，預計將於 2025 年 12 月 11 日完成</p>

<p>CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. <strong>®</strong> (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the pricing of its previously announced underwritten public offering of 11,851,853 shares of its common stock at a public offering price of $13.50 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,111,193 shares of common stock at a public offering price of $13.499 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.001 per share exercise price of each pre-funded warrant. The gross proceeds to Fulcrum from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $175.0 million. In addition, Fulcrum has granted the underwriters a 30-day option to purchase up to an additional 1,944,456 shares of its common stock on the same terms and conditions. All of the securities in the offering are to be sold by Fulcrum.</p>
<div class="lb-trans"><p>馬薩諸塞州劍橋，2025 年 12 月 10 日（環球新聞通訊社）—— Fulcrum Therapeutics, Inc. <strong>®</strong>（“Fulcrum”）（納斯達克：FULC）是一家臨牀階段的生物製藥公司，專注於開發小分子藥物以改善基因定義的罕見疾病患者的生活，今天宣佈其之前宣佈的公開承銷發行的定價，發行 11,851,853 股普通股，公開發行價格為每股 13.50 美元，並且為了某些投資者提供預先融資的認股權證，以購買最多 1,111,193 股普通股，公開發行價格為每個預先融資認股權證 13.499 美元，這代表每股普通股的公開發行價格減去每個預先融資認股權證的 0.001 美元行使價格。Fulcrum 預計此次發行的總收入在扣除承銷折扣和佣金及其他發行費用之前，將達到 1.75 億美元。此外，Fulcrum 已授予承銷商一個 30 天的選擇權，以相同條款和條件購買最多 1,944,456 股普通股。所有發行的證券均由 Fulcrum 出售。</p>
</div><p>Fulcrum currently intends to use the net proceeds from the sale of the securities offered in the public offering primarily for general corporate purposes, which may include working capital and capital expenditures, research and development expenses, including to fund clinical trials, regulatory submissions, commercialization, discovery and additional preclinical research and development of additional product candidates and platform enhancement, general and administrative expenses, and potential acquisitions of, or investments in, companies, technologies, products or assets that complement its business.</p>
<div class="lb-trans"><p>Fulcrum 目前打算將公開發行中證券銷售的淨收益主要用於一般企業用途，這可能包括營運資金和資本支出、研究與開發費用，包括資助臨牀試驗、監管提交、商業化、發現及額外的臨牀前研究與開發其他產品候選者和平台增強、一般和行政費用，以及潛在的收購或投資於補充其業務的公司、技術、產品或資產。</p>
</div><p>J.P. Morgan, Leerink Partners, and Cantor are acting as book-running managers for the offering. Oppenheimer &amp; Co. and Truist Securities are also acting as book-running managers for the offering. The offering is subject to the satisfaction of customary closing conditions and expected to close on or about December 11, 2025.</p>
<div class="lb-trans"><p>摩根大通、Leerink Partners 和 Cantor 擔任此次發行的賬簿管理經理。Oppenheimer &amp; Co.和 Truist Securities 也擔任此次發行的賬簿管理經理。此次發行需滿足慣例的成交條件，預計將於 2025 年 12 月 11 日左右完成。</p>
</div><p>The securities are being offered by Fulcrum pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 27, 2024 and declared effective by the SEC on April 25, 2024. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on December 8, 2025 and is available on the SEC’s website at www.sec.gov, and a final prospectus supplement and accompanying prospectus relating to the final terms of the offering will be filed with the SEC.</p>
<div class="lb-trans"><p>這些證券是由 Fulcrum 根據之前於 2024 年 2 月 27 日向美國證券交易委員會（“SEC”）提交併於 2024 年 4 月 25 日獲得 SEC 批准的有效貨架註冊聲明進行發行的。此次發行僅通過書面招股説明書和招股説明書補充進行，這些文件構成註冊聲明的一部分。與此次發行相關的初步招股説明書補充及相關招股説明書已於 2025 年 12 月 8 日向 SEC 提交，並可在 SEC 的網站 www.sec.gov 上獲取，最終的招股説明書補充及相關招股説明書將與最終條款一起提交給 SEC。</p>
</div><p>When available, copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmorgan.com and postsalemanualrequests@broadridge.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; Cantor Fitzgerald &amp; Co. by mail at Attention: Capital Markets, 110 East 59th Street, New York 10022 or by email at prospectus@cantor.com; Oppenheimer &amp; Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, or by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com; or Truist Securities, Inc., Attention: Equity Capital Markets, 740 Battery Ave SE, Atlanta, Georgia 30339, by telephone at (800) 685-4786 or by email at truistsecurities.prospectus@truist.com.</p>
<div class="lb-trans"><p>當可用時，關於此次發行的最終招股説明書補充及相關招股説明書的副本可從摩根大通證券有限責任公司獲取，地址為：Broadridge Financial Solutions，1155 Long Island Avenue，Edgewood，NY 11717，或通過電子郵件發送至 prospectus-eq_fi@jpmorgan.com 和 postsalemanualrequests@broadridge.com；Leerink Partners LLC，注意：承銷部門，53 State Street，40th Floor，Boston，MA 02109，電話（800）808-7525，分機 6105，或通過電子郵件發送至 syndicate@leerink.com；Cantor Fitzgerald &amp; Co.，郵寄地址：注意：資本市場，110 East 59th Street，New York 10022，或通過電子郵件發送至 prospectus@cantor.com；Oppenheimer &amp; Co. Inc.，注意：承銷招股説明書部門，85 Broad Street，26th Floor，New York，NY 10004，或電話（212）667-8055，或通過電子郵件發送至 EquityProspectus@opco.com；或 Truist Securities, Inc.，注意：股本資本市場，740 Battery Ave SE，亞特蘭大，喬治亞州 30339，電話（800）685-4786 或通過電子郵件發送至 truistsecurities.prospectus@truist.com。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售這些證券的要約或購買這些證券的要約邀請，也不應在任何州或司法管轄區內進行這些證券的銷售，若在任何此類州或司法管轄區內的證券法下未進行註冊或資格審查，則該等要約、邀請或銷售將是非法的。</p>
</div><p><strong>About Fulcrum Therapeutics</strong></p>
<div class="lb-trans"><p><strong>關於 Fulcrum Therapeutics</strong></p>
</div><p>Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.</p>
<div class="lb-trans"><p>Fulcrum Therapeutics 是一家臨牀階段的生物製藥公司，專注於開發小分子藥物，以改善在高未滿足醫療需求領域中基因定義的罕見疾病患者的生活。Fulcrum 的主要臨牀項目是 pociredir，這是一種旨在增加胎兒血紅蛋白表達以治療鐮狀細胞病的小分子。Fulcrum 利用專有技術識別可以調節基因表達以治療基因誤表達已知根本原因的藥物靶點。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the completion of the public offering and the use of proceeds from the public offering. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties related to fluctuations in Fulcrum’s stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering, as well as the other factors discussed in the “Risk Factors” section in the prospectus supplement and registration statement referenced above and in Fulcrum’s most recently filed Quarterly Report on Form 10-Q, as well as other risks detailed in Fulcrum’s filings with the Securities and Exchange Commission. There can be no assurance that Fulcrum will be able to complete the public offering on the anticipated terms. All information in this press release is as of the date of the release, and Fulcrum undertakes no duty to update this information, even if subsequent events cause its views to change, unless required by law.</p>
<div class="lb-trans"><p>本新聞稿包含 1995 年《私人證券訴訟改革法案》所定義的 “前瞻性聲明”，包括但不限於關於公開發行的完成及其收益使用的聲明。所有這些前瞻性聲明均基於管理層對未來事件的當前預期，並受到多種風險和不確定性的影響，這些風險和不確定性可能導致實際結果與這些前瞻性聲明中所列或暗示的結果存在重大和不利的差異。這些風險和不確定性與 Fulcrum 的股價波動、市場條件變化以及與公開發行相關的慣常成交條件的滿足有關，以及在上述招股説明書補充文件和註冊聲明的 “風險因素” 部分中討論的其他因素，以及 Fulcrum 最近提交的 10-Q 表格季度報告中詳細列出的其他風險。不能保證 Fulcrum 能夠按照預期條款完成公開發行。本新聞稿中的所有信息均截至發佈之日，Fulcrum 不承擔更新該信息的義務，即使後續事件導致其觀點發生變化，除非法律要求。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>聯繫方式：</strong></p>
</div><p>Kevin Gardner</p>
<div class="lb-trans"><p>Kevin Gardner</p>
</div><p>LifeSci Advisors, LLC</p>
<div class="lb-trans"><p>LifeSci Advisors, LLC</p>
</div><p>kgardner@lifesciadvisors.com</p>
<div class="lb-trans"><p>kgardner@lifesciadvisors.com</p>
</div><p>617-283-2856</p>
<div class="lb-trans"><p>617-283-2856</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01EQXhOU00zTXpFMU5UTTVJekl4T0RNMU5EST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMDAxNSM3MzE1NTM5IzIxODM1NDI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Mzc4ZGRiYTEtNWUzMS00MTFjLThjOTgtNDRiYzZmNzlkY2MxLTExOTUxMDAtMjAyNS0xMi0xMC1lbg==/tiny/Fulcrum-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/Mzc4ZGRiYTEtNWUzMS00MTFjLThjOTgtNDRiYzZmNzlkY2MxLTExOTUxMDAtMjAyNS0xMi0xMC1lbg==/tiny/Fulcrum-Therapeutics-Inc-.png"/></p>

Fulcrum Therapeutics 宣佈擴大規模的 1.75 億美元普通股和預付款認股權證公開發行的定價 | FULC 股票新聞